BridgeBio reports Q2 EPS (95c), consensus (61c)

Reports Q2 revenue $110.57M, consensus $88.78M. The $108.4M increase in total revenues, net was due to a $71.5M increase in net product revenue for our commercial product, Attruby, a $35.3M increase in license and services revenue largely due to the $30M regulatory milestone recognized under the license agreement with Alexion upon pricing approval of Beyonttra from the National Health Insurance in Japan in May and a $1.6M increase in royalty revenue earned on net product sales of Beyonttra in the EU and Japan. “Attruby’s latest results showcase the power of pairing breakthrough scientific excellence with disciplined commercial execution,” said Matt Outten, Chief Commercial Officer of BridgeBio (BBIO). “Product revenue nearly doubled this quarter, driven by growing adoption across centers of excellence and community physicians. With increasing demand and best-in-class patient access programs, we are confident Attruby will become the standard of care for ATTR-CM, setting the foundation for three additional rare disease launches in 2026 and 2027.”